WSP.TO 2.79COST -9.67TECK.B.TO -0.01ORCL 4.74SHOP.TO -0.2CDNS -12.175BRK.B -2.1ARGT -0.39
Amgen Inc. (AMGN)

NASDAQ:AMGN

Amgen Inc. (AMGN)

437.23
-6.89 (1.55%)
as of Sep 4, 2026, 8:00:00 pm Market Open.
107 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 4, 2026, 12:00 am

This summary was created by AI, based on 16 opinions in the last 12 months.

Amgen Inc. (AMGN-Q) is seen as a well-managed and innovative biotech company that has shown impressive performance in its recent earnings reports, surpassing expectations in both revenue and profit margins. Analysts highlight a robust pipeline, with 15 of its products experiencing double-digit sales growth, which suggests strong ongoing demand for their offerings. Additionally, Amgen's work in GLP-1 drugs, including a potential game-changing product in phase 3 testing, has garnered positive sentiment, alongside its attractive dividend yield. Overall, experts suggest holding the stock for long-term gains, with a favorable outlook considering the current market trends and the company's positioning within the biotech sector.

consensus icon
Consensus
Positive
valuation icon
Valuation
Undervalued
review icon
Similar
Gilead, GILD
WAIT

Amgen Inc.(AMGN)

Mar 01, 2021
It has been under-performing the overall market. Biotechs don't do well at this point seasonally. Its seasonal period starts in June and the trade could setup quite well. Don't look at it at this time.
Photo of Brooke ThackrayBrooke ThackrayUnlock Rating
$226.90

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Amgen Inc.(AMGN)

Nov 03, 2020

Stockchase Research Editor: Michael O'Reilly AMGN just released earnings and the 12% increase in revenues and 5% increase in EPS were likely held back due to government mandates to focus health spending towards COVID-19 projects. The company is now benefitting from the release of new arthritis and metastatic colorectal cancer treatments. They also signed a deal to partner with Eli Lilly to manufacture a coronavirus antibody treatment, when it is ready. They pay a good dividend, backed by a 50% payout ratio. We would trade this with a stop-loss of $205 and a target of of $255 -- over 15% upside. Yield 2.91% (Analysts’ price target is $254.12)

Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$218.95

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
WATCH

Amgen Inc.(AMGN)

Oct 20, 2020
A pure biotech company with a strong biosimilar business with a great core franchise in immunology. Their oncology business is also robust. They had a recent miss in one of their trials, which was the second miss this year. (There is another phase 3 trial this year.) He wants to see either more execution on their R&D drugs or backfill through some M&A in coming years. He's closely watching this.
Photo of Paul MacDonaldPaul MacDonald
No
Unlock Rating
$232.54

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Amgen Inc.(AMGN)

Sep 29, 2020
It has a lot of irons in the fire including an oncology franchise they're not getting any credit for.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$248.30

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Amgen Inc.(AMGN)

Sep 18, 2019
The biotech grandddaddy. A great company that's produced some fine drugs, but other technologies have taken the shine off this stock. New drugs haven't driven the stock up. It does trade at a reasonable 11x earnings. A decent stock and it's stable, but lacks the punch of its peers. It depends what happens in the US election in Nov. 2020 too.
Photo of Gordon ReidGordon ReidUnlock Rating
$195.04

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Amgen Inc.(AMGN)

Jul 17, 2019
(A Top Pick Jul 05/18, Up 3%) One of the world's largest biotech companies. They have 3-4 blockbuster drugs in the pipeline in phase 1 & 2. It's an under-owned stock. Enbrel, their largest-selling drug, is undergoing a parent review. If Amgen wins--which he thinks will happen--then there'll be a 12% stock boost; if not, it will fall 12%. Either way, after this review, Amgen is still worth buying.
Photo of Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$177.06

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
PARTIAL SELL

Amgen Inc.(AMGN)

Jul 09, 2019
It has a nice head and shoulders, with a double-top at $210. It's now at a shoulder around $180. It needs to rise above this level. Continue to hold it or sell.
Photo of Elliott FishmanElliott FishmanUnlock Rating
$181.59

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Amgen Inc.(AMGN)

May 23, 2019
Great product but the are matured. he prefers other Health Care names.
Photo of Bruce MurrayBruce Murray
No
Unlock Rating
$172.11

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

May 03, 2019
Large cap diversified biotech company. Seeing shorts because of a patent dispute. Diversified pipeline of drugs. Valuation is attractive. Buy this as a basket. Yield is 3.27%. (Analysts’ price target is $206.95)
Photo of Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$177.31

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
WAIT

Amgen Inc.(AMGN)

Apr 30, 2019
It's been in a choppy uptrend since 2017, and is now consolidating. Lows are around $180 and now testing that area. If it breaks out, it would be positive. Otherwise, it's wait and see.
Photo of Keith RichardsKeith RichardsUnlock Rating
$179.32

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Amgen Inc.(AMGN)

Apr 22, 2019
The grandaddy of the biotechs, a good solid holding, trading at 14x earnings. But it lacks a catalyst.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$176.36

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Amgen Inc.(AMGN)

Dec 03, 2018
(A Top Pick Jul 05/18, Up 10%) He held onto this over the summer, despite expecting autumnal volatility. It's a diversified biotech and big in bio-similars, so AMGN would benefit from an uptick here. It's reasonably priced.
Photo of Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$202.93

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
WAIT

Amgen Inc.(AMGN)

Oct 19, 2018

Had owned it for a number of years but sold it recently. The growth trajectory going forward was slowing. Still pretty cheap and great cash flow. For him to get back into this stock, it would have to be significantly lower.

Photo of Bryden TeichBryden Teich
No
Unlock Rating
$201.80

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Jul 05, 2018

One of the leading biotech firms. They have a number of new drugs that came out. Dividend yield of 2.8%. Market cap of $124 billion. (Analysts’ price target is $196.95)

Photo of Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$187.36

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Amgen Inc.(AMGN)

Nov 02, 2017

Pharmaceutical stocks have had a much more difficult time because of the presidential election, a time when they usually fall. However, they've bounced back as much as they normally do. This is not expensive. Trading at about 14X earnings and pays a nice dividend yield. Has some really great drugs in their pipeline. It continues to outperform on an earnings basis. He really likes this.

Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$172.41

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
Showing 61 to 75 of 166 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NXE.TO 0.16$14.89
ATD.TO 0.09$82
T.TO -0.01$13.39
KKR -2.03$107.73
CSU.TO -17.42$3023.96

Today's Top Picks

WSP.TO 2.79$186.86
COST -9.67$915.74
TECK.B.T… -0.01$13.39
ORCL 4.74$158.78
SHOP.TO -0.2$200.76

Popular Articles

Latest Sell Signals

LULU -21.19$100.58
CVX -2.72$208.6
ZQQ.TO 0.46$199.22
SOXX 17.66$519.86
AAPL -8.24$319.97

Most Recent Experts

Brian Madden

Brian Madden

First Avenue Investment Counsel

Kim Bolton

Kim Bolton

Black Swan Dexteritas

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

You may also like